Varying Impact of Lenvatinib or Sorafenib Therapy on Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma.
Yurika YamauchiIssei SaekiKoichi FujisawaMaho EgusaNatsuko NishiyamaTsuyoshi FujiokaDaiki KawamotoRyo SasakiTatsuro NishimuraNorikazu TanabeTakuro HisanagaToshihiko MatsumotoTsuyoshi IshikawaTakahiro YamasakiTaro TakamiPublished in: Oncology (2024)
Sorafenib may have a more negative effect on skeletal muscle than lenvatinib.